Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 May 21;8(5):e62. doi: 10.1002/hem3.62

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 The Authors. HemaSphere published by John Wiley & Sons Ltd. on behalf of European Hematology Association.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Multivariate analysis (MVA) for patients receiving treatment after CAR T‐cell therapy progression. (A) MVA for progression‐free survival. (B) MVA for overall survival. Footnote shows values of ECOG, LDH, and IPI at the time of CAR T‐cell therapy. BsAbs, bispecific antibodies; CI, confidence interval; CR, complete response; CT, chemotherapy; ECOG, Eastern Cooperative Oncology Group; ICI, immune checkpoint inhibitors; IPI, International Prognostic Index; LDH, lactate dehydrogenase; LENA, lenalidomide; PD, progressive disease; POLA, polatuzumab–bendamustine–rituximab; PR, partial response; RT, radiotherapy; SD, stable disease; ULN, upper limit of normal.